FDA OKs First Cellular Therapy for Melanoma
The FDA approved the cellular therapy lifileucel (Amtagvi) for the treatment of patients with previously treated unresectable or metastatic melanoma, the agency announced Friday. Lifileucel, a cellular therapy with tumor-infiltrating lymphocytes (TILs), was approved through the accelerated approval pathway, and is the first FDA-approved tumor-derived T-cell immunotherapy, the FDA noted. “Unresectable or metastatic melanoma is […]
More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancer
Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved progression-free survival (PFS) versus either agent alone, according to findings from a small phase II trial presented at this year’s Genitourinary Cancers Symposium. In this exclusive MedPage Today video, Daniel Geynisman, MD, of Fox Chase […]
New Standard for Unresectable Hepatocellular Carcinoma?
SAN FRANCISCO — After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed. Patients who received durvalumab (Imfinzi) plus bevacizumab (Avastin) in addition to TACE had a median progression-free survival (PFS) of 15.0 months as compared with 8.2 months for TACE […]
Why Do My Symptoms Go Away Once I Arrive At My Doctor’s Office?
LOADINGERROR LOADING Maybe you’ve had a horrible week, but by the time your therapy session rolls around, you feel fine. Or maybe you’ve been feeling sick at home, but once you walk into your doctor’s office, all those symptoms disappear. Going to see a health care provider while you’re not actually experiencing otherwise bothersome symptoms […]
More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effects
Men treated with androgen deprivation therapy (ADT) for prostate cancer had a significantly higher risk of dementia and other neurocognitive disorders, according to a meta-analysis of more than 2.5 million patients. The magnitude of excess risk ranged from 20% for dementia to 66% for depression. The risk of Alzheimer’s disease, vascular dementia, and Parkinson’s disease […]
Testosterone for Hypogonadism Cleared So Far of Prostate Cancer Risk
Men treated with testosterone replacement therapy (TRT) for hypogonadism didn’t have an increase in adverse prostate events, the TRAVERSE trial found. Over a mean follow-up of 33 months, those who used topical 1.62% testosterone gel had a 0.19% incidence of high-grade prostate cancer (Gleason score ≥4 + 3), similar to the 0.12% among placebo-treated men […]
DAPT Stays Helpful for Minor Stroke Even With Later Presentation, Worse Symptoms
The benefit of dual antiplatelet therapy (DAPT) for a minor ischemic stroke seems to apply outside the 24-hour time window and minimal stroke symptoms for which the treatment is currently recommended, based on results from the INSPIRES trial. Administered within 72 hours after onset of mild ischemic stroke or high-risk transient ischemic attack (TIA), the […]
Clinical Challenges: Test Your Knowledge of Breast Cancer
A MedPage Today Clinical Challenges series on breast cancer reviewed locoregional therapy for older patients, the management of invasive lobular cancer (ILC), and the treatment of advanced hormone receptor (HR)-positive disease post-CDK4/6 inhibition. The following is a three-question quiz to test your knowledge on each aspect of the series. Correct answers and explanations appear after […]
Sharp Uptick in Gender-Affirming Hormone Therapy Visits After ACA’s Passage
Healthcare visits for transgender-related diagnoses and gender-affirming hormone therapy (GAHT) have been rising, researchers reported, suggesting it as an opportunity for HIV prevention. Within a commercial health plan database, the proportion of adults with a transgender-related diagnosis code increased by 30.8% each year from 2014 to 2021 (13.4 to 113.9 per 100,000 enrolled persons) for […]
Very Early ART Can Result in Sustained HIV Suppression in Neonates
In neonates with acquired in utero HIV infection, administration of antiretroviral therapy (ART) within 48 hours of life can lead to sustained HIV virological suppression by 2 years, a phase I/II proof-of-concept study indicated. In two cohorts who received three-drug nevirapine-based ART regimens within two days of life and maintained protocol- defined virological control criteria […]